Is NCT05031897 recruiting in Philadephia, PA?

Yes, NCT05031897 is currently recruiting participants at its Philadephia, PA location. This acute lymphoblastic leukemia clinical trial is actively enrolling qualified participants.

How do I join the acute lymphoblastic leukemia clinical trial in Philadephia?

To join this clinical trial in Philadephia, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Philadephia clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Acute Lymphoblastic Leukemia Clinical Trial in Philadephia, PA

About This Acute Lymphoblastic Leukemia Study in Philadephia

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation therapy uses high energy sources to kill cancer cells and shrink tumors while chemotherapy drugs like fludarabine and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study evaluates whether a two-step approach with lower-intensity regimens of these treatments prior to HSCT reduces the rate of TRM.

Sponsor: Thomas Jefferson University

Who Can Participate

Inclusion Criteria

Radiation-based cohort diagnoses:

Acute myeloid leukemia

Acute lymphoid leukemia in remission

Myelodysplasia (MDS)

Chronic lymphocytic leukemia (CLL) with no or minimal lymph node involvement

Multiple myeloma

Chronic myeloid leukemia

Myelofibrosis

Myeloid malignancy not otherwise specified

Chronic myelomonocytic leukemia

Essential thrombocytopenia or polycythemia vera

T cell leukemia

T cell lymphoma without significant lymph node disease burden

Any hematological malignancy or dyscrasia not cited above in which HSCT is potentially curable

Any patient who has a hematological disease that would normally be treated on a myeloablative study, but is prevented from doing so by factors in their past medical history. Examples are patients with previous treatment with radiation therapy precluding total-body irradiation (TBI), or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen.

Patients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)

Chemotherapy-based cohort diagnoses:

Hodgkin or non-Hodgkin lymphoma

Small lymphocytic lymphoma/CLL

Any other diagnosis in which chemotherapy is thought to be superior to radiotherapy for treatment of the disease

Hematological malignancy in patients who cannot receive \> 2 Gy radiation

Aplastic anemia and other non-malignant hematologic dyscrasias

Patients must have a donor who is one-haplotype mismatched (number of mismatches in either direction not considered)

Human leukocyte antigen (HLA) identical cohort diagnoses: \

Patients in this group will be treated in parallel to the radiation-based cohort or the chemotherapy-based group based on what category their diagnosis falls into. However, these patients will have HLA identical related donors (one-antigen cross-over event included).

Left ventricular ejection fraction of \>= 50%

Diffusion lung capacity of oxygen \>= 50% and forced expiratory volume at 1 second \>= 50% of predicted corrected for hemoglobin

Serum bilirubin =\< 1.8

Aspartate aminotransferase or alanine aminotransferase =\< 2.5 x upper limit of normal

Creatinine clearance of \>= 60 mL/min

Patients must have adequate Karnofsky performance status (KPS) and Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) scores:

Patients \< age 60 years must have a KPS of \>= 60% and an HCT-CI score of 5 or less

Patients aged 60 to 65 years must have a KPS of \>= 60% and an HCT-CI score of 4 or less

Patients aged 66 to 69 years must have a KPS of 90% and an HCT-CI score of 3 or less

Patients aged 70 years or more must have a KPS of 90% and an HCT-CI score of 2 or less

(Patients with greater than the allowable HCT-CI points for age can be enrolled for trial with approval of the principal investigator (PI) and at least 1 co-investigator (CI) not on the primary care team of the patient). This is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than guideline HCT-CI points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities

Patients must be willing to use contraception if they have childbearing potential

Patient or patient's guardian is able to give informed consent

Patients should have a life expectancy of \>= 6 months for reasons other than their underlying hematologic/oncologic disorder

Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol

Patients should not be:

Human immunodeficiency virus positive

Have active involvement of the central nervous system with malignancy. This can be documented by a normal neurological exam, magnetic resonance imaging (MRI) of the head, and/or a negative cerebral spinal fluid analysis

Pregnant or breastfeeding

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadephia?

Yes, this clinical trial (NCT05031897) has an active research site in Philadephia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Lymphoblastic Leukemia Treatment Options in Philadephia, PA

If you're searching for acute lymphoblastic leukemia treatment options in Philadephia, PA, this clinical trial (NCT05031897) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadephia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute lymphoblastic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute lymphoblastic leukemia clinical trials near you to find additional studies recruiting in your area.

Acute Lymphoblastic Leukemia Clinical Trial in Philadephia, PA

Expert Care in Philadephia

IRB Approved

No-Cost Care

Apply for This Philadephia Location

Why Participate?

Simple Process